Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
View Patent ↗Disclosed are methods for producing fusion proteins with the heterodimeric cytokine, interleukin-12. In order to insure that the proper ratio of fused and non-fused subunits are obtained in the fusion protein, a specific stepwise approach to genetic engineering is used. This consists of first expressing the non-fused p40 IL-12 subunit in a production cell line, followed by or simultaneously expressing in the same cell, a second recombinant fusion protein consisting of the fused polypeptide linked by a peptide bond to the p35 subunit of IL-12. Molecules containing the p35 fusion protein cannot be secreted from the transfected mammalian cell without first complexing in a one to one ratio with the p40 subunit, thus ensuring the production of active heterodimeric fusion proteins.
1. A nucleic acid encoding a fusion protein comprising an immunoglobulin (Ig) moiety linked by a peptide bond to the p35 subunit of interleukin-12 (IL-12).
2. The nucleic acid of claim 1 , wherein the Ig moiety comprises a single-chain Fv (scFv) antibody, the scFv antibody comprising an Ig heavy chain variable region and an Ig light chain variable region.
3. The nucleic acid of claim 2 , wherein the Ig light chain variable region is N-terminal relative to the Ig heavy chain variable region.
4. The nucleic acid of claim 1 , wherein the p35 subunit of IL-12 is linked to the amino terminus of the Ig moiety.
5. The nucleic acid of claim 4 , wherein the p35 subunit of IL-12 is linked to the amino terminus of an Ig heavy chain.
6. The nucleic acid of claim 1 , wherein the Ig moiety has antigen-binding specificity.
7. The nucleic acid of claim 1 , further comprising a promoter to regulate expression of the fusion protein.
8. An isolated cell comprising the nucleic acid of claim 7 .